Seroepidemiology and Risk Factors of Hepatitis B Virus Infection: A Population-Based Azar Cohort Study
Background: Hepatitis B is a major global health problem. It can cause chronic infections and put people at high risk of death from cirrhosis and hepatocellular carcinoma. The aim of this study was to report the epidemiological features of hepatitis B virus (HBV) infection and risk factors based on the data from Azar Cohort.
Methods: The population of this study comprised the people in the age range of 35-70 yr from Azar cohort, East Azerbaijan Province, Iran between 2015 and 2016. Based on cluster sampling, 4,949 people were selected and invited to complete the questionnaire and perform the tests. Blood samples were analyzed for serum HBV markers (HBsAg, HBsAb and HBcAb) by ELFA method. The data were analyzed using SPSS statistical software.
Results: The mean (SD) age of the participants was 49.15 ± 9.02 years. The frequency rates of HBsAg, HBsAb and HBcAb were estimated as 1.03%, 16.9% and 24.95%, respectively. There was statistically significant association between family history of hepatitis (P<0.001) and jaundice history (P<0.001) with the presence of HBsAg. There was also a positive correlation between marital status (P=0.002), history of hospitalization (P<0.001), smoking (P=0.001), dental procedures (P<0.001), foreign travels (P=0.005), occupation status (P=0.002) and the presence of HBcAb.
Conclusion: The frequency of hepatitis B in Azar Cohort was 1.03% which is a lower rate compared with other reports from Iran. The association of the population studied and the increase of public awareness in this area can probably prevent this disease.
Van Damme P, Moiseeva A, Marichev I et al (2010). Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years. BMC infectious Diseases, 10 (357):1-8.
Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009.Hepatology, 50(3):661-2.
Wright TL (2006). Introduction to chronic hepatitis B infection. Am J Gastroenterol, 101 Suppl 1:S1- 6 .
World Health Organization (2016). Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: World Health Organization. Available from: http://www.who.int/iris/handle/10665/206453
Merican I, Guan R, Amarapuka D et al (2000). Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol, 15(12):1356–61.
Song le H, Xuan NT, Toan NL et al (2008). Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. Eur Cytokine Netw, 19(4):204-10.
Weinbaum CM, Williams I, Mast EE et al (2008) .Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep, 19; 57(RR-8):1-20.
Ott JJ, Stevens GA, Groeger J et al (2012). Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 30(12):2212–9.
Zali MR, Mohammad K, Noorbala AA et al (2005). Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J, 11(1-2):62–7.
Alavian SM, Hajarizadeh B, Ahmadzad-Asl M et al (2008). Hepatitis B virus infection in Iran: A systematic review. Hepatitis Mon, 8(4):281–94.
Hajarizadeh B, Mesgarpour B, Nasiri MJ et al (2017). Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran. Hepat Mon, 17(8):e11715.
Alavian SM, Fallahian F, Lankarani KB (2010). Implementing strategies for hepatitis B vaccination. Saudi J Kidney Dis Transpl, 21(1):10–22.
Mohammadzadeh M, Fattahi B, Ghari T (2017) .The estimation of economic burden of hepatitis B virus infection in Iran. Hepat Mon, 17(1):e40541.
Shakeri MT, Foghanian B, Nomani H et al (2013). The prevalence of hepatitis B virus infection in Mashhad, Iran: a population-based study. Iran Red Cres J, 15(3): 245-8.
Alavian SM, Tabatabaei SV, Nourizad S et al (2012). Seroepidemiology of HBV infection in Kermanshah- West of Iran; a population-based study. Jundishapur J Microbiol, 5(4):564-9.
Moezzi M; Imani R; Khosravi N et al (2014). Hepatitis B seroprevalence and risk factors in adult population of Chaharmahal and Bakhtiari Province in 2013. Hepat Mon, 14(5): e17398.
Ziaee M, Ebrahimzadeh A, Azarkar Z et al (2016). Seroprevalence and risk factors for hepatitis B in an adult population: the first report from Birjand, South Khorasan, Iran. Hepat Mon, 16(9):e36452.
Keyvani H; Sohrabi M; Zamani F et al (2014). A population based study on hepatitis B virus in northern Iran, Amol. Hepat Mon, 14(8): e20540.
Merat S, Rezvan H, Nouraie M et al (2009). The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med, 12(3):225–31.
Ghadir MR, Belbasi M, Heidari A et al (2012). Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. Hepat Mon, 12(2):112–7.
Kim, W (2009). Epidemiology of hepatitis B in the United States, Hepatology, 49(S5):p. S28 -S34.
Hamied L, Mujahid Abdullah R, Mujahid Abdullah A (2010). Seroprevalence of Hepatitis B and Hepatitis C virus infection in Iraq. The N Iraqi J Med, 6(3): 69-73.
Jue Liu, Shikun Zhang, Qiaomei Wang et al (2016). Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis, 16: 80–86.
Nokhodian Z, Kassaian N, Ataei B et al (2009). Hepatitis B markers in Isfahan, central Iran: a population-based study, Hepatitis Monthly, 9(1): 12-16.
Ansari-Moghaddam A, Ostovaneh MR, Sharif Mood B et al (2012). Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in Zahedan city, Iran: a population-based study. Hepat Mon, 12(9):e6618.
N Abdollahi, AA Keshtkar, SH Semnani et al (2006). HBV seroprevalence among Golestan adults . IRJE, 2(3 And 4): 35-40[In Persian].
Alter MJ, Margolis HS (1990). The emergence of hepatitis B as a sexually transmitted disease. Medical clinics of North America, 74: 1529-41.
Yentur Doni N; Simsek Z; Keklik Z et al (2014). Epidemiology of hepatitis B in the reproductive-age female farmworkers of southeastern Turkey. Hepat Mon, 14(11): e22120.
Zhang HW, Yin JH, Li YT et al (2008). Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut, 57(12):1713-20.
Merat S, Rezvan H, Nouraie M et al (2009).The prevalence of hepatitis B surface antigen and anti hepatitis B core antibody in Iran: a population-based study. Arch Iran Med, 12(3):225–31.
Behzad-Behbahani A, Maf-Nejad A, Tabei SZ et al (2006). Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res, 123(1):37–42.
Salehi M, Alavian SM, Tabatabaei SV et al (2012). Seroepidemiology of HBV infection in South-East of Iran; a population based study. Iran Red Crescent Med J, 14(5):283–8.
|Issue||Vol 49 No 11 (2020)|
|Hepatitis B virus Seroepidemiology Iran|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|